Conference abstract · 26 Oct 2016
Conference abstractPublished 26 Oct 2016
Inside track to an orphan designation
Cote Orphan LLC, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
All too often, creators of new therapies for people with rare diseases will expend vast resources on drug discovery, manufacturing, clinical key opinion leaders and of course raising money but ignore regulatory affairs, assuming that will just itself somehow work out. In this presentation, Dr. Cote, previous Director of the FDA orphan drug office, will discuss the intricacies of the orphan drug designation in the US and in Europe, preparing for a winning pre-IND meeting, crafting clinical trials that make sense to regulators, special incentives like breakthrough therapy designation, the pediatric rare disease designation and the PRIME program will also be demystified.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Insider insight on the orphan drug act
Conference abstract · 8 Jun 2018
Regulatory framework and requirements for orphan drug designation and development programs
Research article · 15 May 2018
Orphan Drug Designations in Ophthalmology
Case report · 2015
Orphan Drug Designation within the Development Strategy
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Timothy R Cote”
